Last reviewed · How we verify
AD-2091
AD-2091 is a small molecule that targets the PI3K/AKT pathway to inhibit cancer cell growth.
AD-2091 is a small molecule that targets the PI3K/AKT pathway to inhibit cancer cell growth. Used for Metastatic breast cancer, Metastatic colorectal cancer.
At a glance
| Generic name | AD-2091 |
|---|---|
| Sponsor | Addpharma Inc. |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AD-2091 works by binding to the PI3K/AKT pathway, which is involved in cell growth and survival. By inhibiting this pathway, AD-2091 can help slow down the growth of cancer cells and prevent their spread.
Approved indications
- Metastatic breast cancer
- Metastatic colorectal cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD-2091 CI brief — competitive landscape report
- AD-2091 updates RSS · CI watch RSS
- Addpharma Inc. portfolio CI